A single genetic abnormality found in more than two-thirds of supratentorial ependymomas, a deadly class of pediatric brain tumors, does far more than activate one inflammatory pathway. The ZFTA-RELA ...

The oral molecular glue degrader aims to overcome resistance to standard ALK tyrosine kinase inhibitor therapies.

"Emerging Fusion Protein Technologies Drive Innovation in Targeted Therapies Across Autoimmune, Cancer, Metabolic, and Cardiovascular Diseases" Boston, Dec. 11, 2025 (GLOBE NEWSWIRE) -- According to ...

TRIANA Biomedicines, Inc. (TRIANA), a leading biopharmaceutical company focused on advancing a target-first and proximity-first molecular glue discovery platform to address difficult to drug disease ...

BUFFALO, N.Y., — Many childhood cancers start with a hijacking at the molecular level. A group of abnormal proteins known as fusion proteins aberrantly engage with a collection of proteins that ...

A study looking at the biophysical properties of an abnormal protein driving cancer cells is giving scientists new therapeutic clues for how to treat ependymoma, the third most common childhood brain ...

A team of researchers at Baylor College of Medicine, St. Jude Children’s Research Hospital, Texas Children’s Hospital and ...

The AI platform for therapeutic antibody and biologics discovery is now open for subscription. SAN FRANCISCO , CA, ...

The Food and Drug Administration has approved more than 100 monoclonal antibodies to treat a range of diseases. Other antibodies are used by physicians to diagnose conditions or by scientists to ...

The Food and Drug Administration has approved more than 100 monoclonal antibodies to treat a range of diseases. Other antibodies are used by physicians to diagnose conditions or by scientists to ...